Lyfspn is a company that is currently planning to carry out a pilot study of their lead longevity promoting therapy candidate, a novel apheresis-based treatment. Apheresis is an existing therapeutic modality which plays an important role in the management of many diseases including more than 50 autoimmune disorders, a number of rare neurologic conditions, and …
The company is physician-led and working to invent novel therapies, enabling customers with a novel apheresis-based treatment. Lyfspn is backed by Khosla Ventures and is conducting a plasmapheresis trial in the Bay Area for longevity benefits.
Investors 1
| Date | Name | Website |
| 22.02.2023 | Khosla Ven... | khoslavent... |